CDTX (Cidara) Prakiraan rega marang bathi

Cidara Therapeutics (CDTX) focuses on advanced R&D in the field of antiviral immunotherapy. The team is developing breakthrough conjugates to shift infection prevention standards. The projected P/E valuation visualizes the business's market value, where 0.00 serves as the current metric level. Cloudbreak technology enables the creation of long-acting drugs, simplifying the treatment of severe diseases.

CDTX - Kapitalisasi marang proyeksi bathi Cidara Therapeutics Corp ing rentang 04.07.2022 - 17.01.2026

Rincian analitis perusahaan Cidara Therapeutics

- rega saiki lan proyeksi nilai saham:

Kutipan saham Cidara Therapeutics|CDTX - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Biji pasar Cidara Corp|CDTX - Nilai Total Perusahaan

- statistik nilai buku emiten:

Nilai Buku saben Saham Cidara|CDTX - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku cidara.com|CDTX - Nilai Agregat Aset

- statistik kawajiban utang lan likuiditas:

Rasio Total Utang marang Ekuitas Cidara Therapeutics|CDTX - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Cidara Therapeutics Inc|CDTX - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Cidara|CDTX - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Cidara|Rasio cepet cidara.com

- statistik bathi lan rasio pasar:

CDTX - Bathi perusahaan|Proyeksi bathi mangsa ngarep Cidara Therapeutics|CDTX - Pangali P/E|Rega marang bathi mangsa ngarep Cidara Corp|CDTX - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Cidara Therapeutics Corp|CDTX - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Cidara|CDTX - Bathi saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan cidara.com|CDTX - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Cidara Therapeutics

- data pendapatan lan penerimaan dodolan:

CDTX - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Cidara Corp|CDTX - Rega marang dodolan|Rasio rega marang prakiraan pendapatan Cidara

Analisis dhasar perusahaan:Cidara Therapeutics

Market expectations for Cidara Therapeutics (CDTX) often precede current financial results. The company's forward P/E ratio is calculated by dividing the market price per share by the expected net income of future periods. This indicator allows for an assessment of the premium paid for future growth. The stability of this metric is supported by long-term raw material procurement for drug production, which minimizes operational risks and ensures the sustainability of the biotech business's profitability.

Pesaing Cidara Therapeutics

Prakiraan rega marang bathi GILD (Gilead Sciences Inc)|NVAX (Novavax, Inc.) - Pangali mangsa ngarep rega marang bathi|CureVac N.V. - Prakiraan rega marang bathi|Valneva SE - Rega marang bathi mangsa ngarep|VIR - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi SIGA Technologies Inc SIGA|EBS (Emergent BioSolutions Inc) - Prakiraan rega marang bathi|Atea Pharmaceuticals - Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi IVVD|Pangali Forward P/E enanta.com|Pangali Forward P/E INO|Kapitalisasi marang proyeksi bathi HilleVax|Rega marang bathi mangsa ngarep Kalaris Therapeutics Inc. KLRS|DYAI: Rasio rega marang bathi mangsa ngarep|NanoViricides, Inc. - Pangali Forward P/E|TLPH - Pangali Forward P/E|COCP: Pangali Forward P/E|Traws Pharma, Inc. (TRAW) - Pangali Forward P/E|Prakiraan rega marang bathi DWTX|Rega marang bathi mangsa ngarep QLGN|Prakiraan rega marang bathi ALVR (AlloVir)|Rega marang bathi mangsa ngarep VBIV (VBI Vaccines)|Rega marang bathi mangsa ngarep virios.com VIRI|Rasio kapitalisasi marang bathi mangsa ngarep VXRT (vaxart.com)